✨ Free AI Report
Perspective Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Perspective Therapeutics, Inc.
Company Research

Perspective Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Perspective Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Early-stage radiopharmaceutical innovator with differentiated TAT technology and strong analyst backing, but success dependent on clinical trial progression. According to 10 analysts, the average rating for CATX stock is "Strong Buy" with a 12-month stock price target of $12.2, representing a 126.77% upside from the latest price. The company.

What is Perspective Therapeutics, Inc.'s industry? Perspective Therapeutics, Inc. (perspectivetherapeutics.com) operates in Radiopharmaceutical Oncology / Targeted Alpha Therapy. AskCyborg classifies Perspective Therapeutics, Inc. under Radiopharmaceutical Oncology / Targeted Alpha Therapy in its company registry.

Perspective Therapeutics develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation s...

7/ 10Strong

Cyborg Score thesis

Early-stage radiopharmaceutical innovator with differentiated TAT technology and strong analyst backing, but success dependent on...

Read the full analyst-debate transcript →
Industry Radiopharmaceutical Oncology / Targeted Alpha Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Perspective Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Perspective Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Perspective Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Perspective Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Perspective Therapeutics, Inc. Overview

Pro stress-test →

Perspective Therapeutics develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. This represents a focused approach to radiopharmaceutical oncology with multiple candidates in clinical development.

Strategic Profile

Pro stress-test →

The company's lead candidate VMT-a-NET is in Phase 1/2a clinical trials for neuroendocrine tumors, while VMT01 targets melanoma, PSV359 targets fibroblast activation protein alpha, and PSV4XX targets prostate-specific membrane antigen. Perspective has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab in melanoma patients.

Competitive Landscape

Pro stress-test →

Perspective competes in the radiopharmaceutical oncology space with candidates targeting multiple tumor types including neuroendocrine tumors (competing with beta-emitting therapies like Lutathera), melanoma, FAP-positive cancers, and PSMA-expressing prostate cancer. The company's alpha-therapy approach differentiation focuses on precision targeting and reduced normal tissue toxicity compared to traditional beta emitters.

Industry Context

Perspective Therapeutics, Inc. operates in Radiopharmaceutical Oncology / Targeted Alpha Therapy.

Key facts

Founded: 2004 · Headquarters: Seattle, Washington · Revenue: $1.45M (2024) · Market cap: $0.614B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Perspective Therapeutics, Inc..

  • Lead candidate VMT-a-NET achieved 76% progression-free survival in neuroendocrine tumors, positioning it favorably versus competitors
  • Recently raised $175 million (Feb 2026) to advance pipeline, with analyst price targets ranging from $6 to $21
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Completed $175 million underwritten offering of common stock and pre-funded warrants
  • Jan 2026Presented updated interim VMT-a-NET Phase 1/2a data at ASCO Gastrointestinal Cancers Symposium
  • +2 moreTrack every material event for Perspective Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Perspective Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LutatheraBeta-emitting somatostatin receptor targeted radiopharmaceutical for neuroendocrine tumors→PluvictoPSMA-targeted beta emitter for castration-resistant prostate cancer→Targeted Alpha TherapiesCompeting alpha-emitter radiopharmaceutical platforms→

Compare Perspective Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Perspective Therapeutics, Inc. operates in Radiopharmaceutical Oncology / Targeted Alpha Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Radiopharmaceutical Oncology / Targeted Alpha Therapy research →
NEW · MCP server

Ask your AI assistant about Perspective Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Perspective Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Perspective Therapeutics, Inc. do this quarter?”
“Is Perspective Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Perspective Therapeutics, Inc. do?+
Perspective Therapeutics develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation s...
What is Perspective Therapeutics, Inc.'s Cyborg Score?+
Perspective Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Perspective Therapeutics, Inc.'s main competitors?+
Named competitors include Lutathera, Pluvicto, Targeted Alpha Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Perspective Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Perspective Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Perspective Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Radiopharmaceutical Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Perspective Therapeutics, Inc.